[1]远 颖.督灸改善慢性阻塞性肺病临床疗效及生存质量的Meta分析[J].医学信息,2022,35(01):93-99.[doi:10.3969/j.issn.1006-1959.2022.01.022]
　YUAN Ying.Meta-analysis of Governor Moxibustion to Improve Clinical Efficacy and Quality of Life of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(01):93-99.[doi:10.3969/j.issn.1006-1959.2022.01.022]
点击复制

督灸改善慢性阻塞性肺病临床疗效及生存质量的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年01期
页码:
93-99
栏目:
论著
出版日期:
2022-01-01

文章信息/Info

Title:
Meta-analysis of Governor Moxibustion to Improve Clinical Efficacy and Quality of Life of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2022）01-0093-07
作者:
远 颖
（天津市中医药研究院肺病科，天津 300120）
Author(s):
YUAN Ying
(Department of Pulmonary Diseases,Tianjin Academy of Traditional Chinese Medicine,Tianjin 300120,China)
关键词:
督灸; 益肺灸; 慢性阻塞性肺病
Keywords:
Governor moxibustion; Lung-benefit moxibustion; Chronic obstructive pulmonary disease
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2022.01.022
文献标志码:
A
摘要:
目的 运用Meta分析方法评价督灸改善慢阻肺稳定期疗效及生存质量的有效性及安全性。方法 计算机检索中国期刊全文数据库（CNKI）、中文科技期刊全文数据库维普（VIP）、中国生物医学文献数据库（CBM）、万方数字化期刊全文库、美国国立医学图书馆（PubMed）、Cochrane Library等数据库，检索玉屏风散治疗慢性阻塞性肺病稳定期的所有随机对照试验（RCT），以FEV1%、FEV1/FVC、MMRC、6MWD、CAT、AECOPD、COPD-PRO、ESQ-COPD作为结局指标。2名评价者独立进行文献检索、以Cochrane Handbook推荐的风险偏倚评估工具行文献质量评价并进行数据提取等工作，讨论解决争议，并采用RevMan 5.3软件进行Meta分析。结果 纳入 11 篇 RCT 文献，涉及 1050 例患者。与常规治疗相比，Meta 分析结果显示：①联合督灸对肺功能第 1 秒用力呼气容积占预计值百分比（FEV1%）[MD=7.08,95%CI（3.24，10.92），P=0.0003]及 FEV1与用力肺活量比值（FEV1/FVC）[MD=9.36,95%CI（1.91，16.80），P=0.01]的改善更佳；②联合督灸能延长 6 min 步行距离[MD=25.82,95%CI（5.59，46.06），P=0.01]；③联合督灸对改良版英国医学研究委员会呼吸问卷（mMRC）分级[MD=-0.57,95%CI（-1.18，0.05），P＜0.00001]的改善更佳；④联合督灸对CAT评分[MD=-3.40，95%CI（-5.82，-0.98），P=0.006]的改善更佳；⑤联合督灸在降低急性加重次数[MD=-0.31,95%CI（-0.49，-0.14），P=0.0005]方面更具优势；⑥联合督灸在改善COPD-PRO水平[MD=-3.24，95%CI（-4.92，-1.57），P=0.0001]方面更具优势；⑦联合督灸在改善ESQ-COPD水平[MD=4.02，95%CI（2.14，5.90），P＜0.0001]方面更具优势；⑧纳入文献均未报告不良反应。结论 督灸联合西医常规治疗干预慢性阻塞性肺病稳定期疗效确切。本研究纳入研究数量偏少，异质性大，证据强度不高，仍需设计高质量临床试验深入研究。
Abstract:
Objective To evaluate the efficacy and safety of governor moxibustion on the efficacy and quality of life of patients with stable chronic obstructive pulmonary disease by Meta-analysis.Methods The Chinese Journal Full-text Database (CNKI), Chinese Science and Technology Periodical Full-text Database (VIP), Chinese Biomedical Literature Database (CBM), Wanfang Digital Journal Full-text Database, United States National Medical Library (PubMed), Cochrane Library and other databases were searched to retrieve all randomized controlled trials (RCTs) of Yupingfeng Powder in the treatment of stable chronic obstructive pulmonary disease. FEV1%, FEV1/FVC, MMRC, 6MWD, CAT, AECOPD, COPD-PRO and ESQ-COPD were used as outcome indicators. Two evaluators independently conducted literature retrieval, conducted literature quality evaluation with the risk bias assessment tool recommended by Cochrane Handbook, and conducted data extraction to discuss and resolve disputes. RevMan 5.3 software was used for Meta-analysis.Results Eleven RCT articles involving 1050 patients were included. Compared with conventional treatment, the results of Meta-analysis showed that: ①combined governor moxibustion had better improvement in the percentage of forced expiratory volume in the first second to the predicted value (FEV1%) [MD=7.08, 95%CI(3.24,10.92), P=0.0003] and the ratio of FEV1 to forced vital capacity(FEV1/FVC) [MD=9.36, 95%CI(1.91,16.80), P=0.01]; ②combined governor moxibustion could prolong the walking distance of 6 min [MD=25.82, 95CI(5.59,46.06), P=0.01]; ③combined governor moxibustion had better improvement in British Medical Research Council Respiratory Questionnaire (mMRC) classification [MD=-0.57, 95%CI(-1.18,0.05),P<0.00001]; ④combined governor moxibustion had better improvement in CAT score [MD=-3.40, 95%CI(-5.82,-0.98), P=0.006]; ⑤combined governor moxibustion had more advantages in reducing the number of acute exacerbations [MD=-0.31, 95%CI(-0.49,-0.14), P=0.0005];⑥combined governor moxibustion had more advantages in improving COPD-PRO level [MD=-3.24,95%CI(-4.92,-1.57), P=0.0001]；⑦combined governor moxibustion had more advantages in improving [MD=4.02,95%CI(2.14,5.90), P＜0.0001];⑧no adverse reactions were reported in the included literature.Conclusion Governor moxibustion combined with routine western medicine treatment is effective in intervening stable phase of chronic obstructive pulmonary disease. The number of studies included in this study is small, the heterogeneity is large, and the evidence strength is not high, so it is still necessary to design high-quality clinical trials for in-depth research.

参考文献/References:

[1]Wang C,Xu J,Yang L,et al.China Pulmonary Health Study Group.Prevalence and risk factors of chronic obstructive pulmonary disease in China （the China Pulmonary Health [CPH] study）: a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.[2]Dekhuijzen PN,van Herwaarden CL,Cox NJ,et al.Exercise training during pulmonary rehabilitation in chronic obstructive pulmonary disease[J].Lung,1990(168 Suppl):481-488.[3]Gloeckl R,Schneeberger T,Jarosch I,et al.Pulmonary Rehabilitation and Exercise Training in Chronic Obstructive Pulmonary Disease[J].Dtsch Arztebl Int,2018,115(8):117-123.[4]Zhang HY,Huang H,Pang LJ,et al.Effectiveness and safety of acupoint application for chronic obstructive pulmonary disease: A protocol for updated systematic review and meta-analysis[J].Medicine (Baltimore),2021,100(18):e25802.[5]刘恒源.透皮外用温散酊治疗痰浊阻肺型慢阻肺急性加重的临床观察[D].北京:北京中医药大学,2021.[6]Huang C,Chen C,Zhou R,et al.A systematic review and meta-analysis of acupoint autohemotherapy and western medicine therapy in treating chronic obstructive pulmonary disease[J].Complement Ther Clin Pract,2021(43):101336.[7]吴琼,郭秀君,孟亚慧,等.温灸法干预COPD的研究现状及可行性分析[J].中医药导报,2019,25(6):108-111,118.[8]Lopez-Campos JL,Soler-Cataluna JJ,Miravitlles M.Global Strategy for the Diagnosis,Management,and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges[J].Arch Bronconeumol (Engl Ed),2020,56(2):65-67.[9]Vogelmeier CF,Criner GJ,Martinez FJ,et al.Global Strategy for the Diagnosis,Management,and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary[J].Am J Respir Crit Care Med,2017,195(5):557-582.[10]周庆伟,杨秦梅.督灸治疗肺肾气虚型慢性阻塞性肺病:随机对照研究[J].中国针灸,2011,31(1):31-34.[11]周庆伟,崔鑫鑫,钱航.益肺灸治疗慢性阻塞性肺疾病稳定期肺肾气虚证的疗效评价[J].时珍国医国药,2016,27(3):649-651.[12]张俊红.督灸对慢性阻塞性肺疾病缓解期肺肾气虚型患者BODE指数的影响[J].中国中医急症,2012,21(6):1005-1006.[13]李纳.益肺灸治疗慢性阻塞性肺疾病稳定期患者临床疗效评价[D].郑州:河南中医学院,2015.[14]杨秀青,符德玉.督灸治疗肺肾气虚型慢性阻塞性肺疾病疗效观察[J].人民军医,2016,59(10):1036-1037.[15]梁国玲,李彬.益肺灸辅助治疗对中重度慢性阻塞性肺疾病患者急性加重次数的影响[J].光明中医,2013,28(3):546-548.[16]王明航,谢洋,史阳琳,等.益肺灸对慢性阻塞性肺疾病稳定期患者生存质量和疗效满意度的影响多中心随机对照研究[J].中医杂志,2019,60(14):1202-1208.[17]王湘雨,王洋,李婷婷.益肺灸辅助治疗稳定期慢性阻塞性肺疾病临床研究[J].新中医,2021,53(16):151-154.[18]范亚男.益肺灸对慢性阻塞性肺疾病生存质量的影响[D].郑州:河南中医药大学,2016.[19]覃光辉,高鹏飞,陈碧琴,等.六孔灸盒灸法治疗稳定期慢性阻塞性肺疾病的临床研究[J].上海针灸杂志,2017,36(7):799-802.[20]赵裕沛,黄宝驹,朱益敏.督灸治疗肺脾肾亏虚型慢性阻塞性肺疾病稳定期疗效观察[J].山西中医,2018,34(9):25-27.

更新日期/Last Update: 1900-01-01